Visium Asset Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENDP
Endo International plc
ENDP
|
+$197M |
| 2 |
AGN
Allergan plc
AGN
|
+$135M |
| 3 |
Bausch Health
BHC
|
+$129M |
| 4 |
CVS Health
CVS
|
+$107M |
| 5 |
McKesson
MCK
|
+$94.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$286M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$225M |
| 3 |
Gilead Sciences
GILD
|
+$86.1M |
| 4 |
Perrigo
PRGO
|
+$79.4M |
| 5 |
Cardinal Health
CAH
|
+$74.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.16% |
| 2 | Consumer Discretionary | 5.06% |
| 3 | Energy | 4.01% |
| 4 | Utilities | 3.23% |
| 5 | Financials | 3.21% |
Similar funds
Visium Asset Management's Q1 2014 Portfolio in Review
As of Q1 2014, Visium Asset Management held 1,163 positions worth $6.18B, up 21% from $5.09B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Visium Asset Management deployed $404M of net new capital in Q1 2014, opening 297 new positions and adding to 261 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 286,563 shares worth $86M.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Energy.
On the sell side, the largest reduction was Allergan Inc, an estimated $286M trimmed.
- Visium Asset Management's largest Q1 2014 buy was Regeneron Pharmaceuticals: 286,563 shares worth $86M.
- Visium Asset Management added most to Endo International plc in Q1 2014, an estimated $197M increase.
- Visium Asset Management's biggest Q1 2014 reduction was Allergan Inc, cutting an estimated $286M.
- Visium Asset Management fully exited Momenta Pharmaceuticals, Inc. in Q1 2014, selling an estimated $64M.
- Visium Asset Management's ten largest holdings make up 32% of its $6.18B portfolio in Q1 2014.
- Visium Asset Management opened 297 new positions and closed 313 in Q1 2014.
- Visium Asset Management's portfolio value rose 21% quarter-over-quarter to $6.18B.
Based on Visium Asset Management's 13F filing for Q1 2014, filed 15 May 2014.